Magaldrate Anhydrous

Summary

Magaldrate Anhydrous (CHEMBL3833408) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 1097.3 Da · Al5H31Mg10O39S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833408
Name	Magaldrate Anhydrous
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	44152596
Molecular formula	Al5H31Mg10O39S2
Molecular weight	1097.3
InChIKey	NNGFFDRXGAELQA-UHFFFAOYSA-A

SMILES: [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3]

IUPAC name: pentaaluminum;decamagnesium;hentriacontahydroxide;disulfate

Also known as: AY-5710

Parent form; salt/anhydrous children: CHEMBL3833350

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).